Substance use disorders, psychiatric disorders, and mortality after release from prison: a nationwide longitudinal cohort study  by Chang, Zheng et al.
422 www.thelancet.com/psychiatry   Vol 2   May 2015
Articles
Lancet Psychiatry 2015; 
2: 422–30
Published Online
April 22, 2015
http://dx.doi.org/10.1016/
S2215-0366(15)00088-7
See Comment page 369
See Online for podcast interview 
with Seena Fazel
Department of Psychiatry, 
Warneford Hospital, University 
of Oxford, Oxford, UK 
(Z Chang PhD, Prof S Fazel MD); 
and Department of Medical 
Epidemiology and 
Biostatistics, Karolinska 
Institutet, Stockholm, Sweden 
(Z Chang, Prof P Lichtenstein PhD, 
H Larsson PhD)
Correspondence to:
Prof Seena Fazel, Department of 
Psychiatry, Warneford Hospital, 
University of Oxford, Oxford 
OX3 7JX, UK
seena.fazel@psych.ox.ac.uk
Substance use disorders, psychiatric disorders, and mortality 
after release from prison: a nationwide longitudinal cohort 
study
Zheng Chang, Paul Lichtenstein, Henrik Larsson, Seena Fazel
Summary
Background High mortality rates have been reported in people released from prison compared with the general 
population. However, few studies have investigated potential risk factors associated with these high rates, especially 
psychiatric determinants. We aimed to investigate the association between psychiatric disorders and mortality in 
people released from prison in Sweden.
Methods We studied all people who were imprisoned since Jan 1, 2000, and released before Dec 31, 2009, in Sweden for 
risks of all-cause and external-cause (accidents, suicide, homicide) mortality after prison release. We obtained data for 
substance use disorders and other psychiatric disorders, and criminological and sociodemographic factors from 
population-based registers. We calculated hazard ratios (HRs) by Cox regression, and then used them to calculate 
population attributable fractions for post-release mortality. To control for potential familial confounding, we compared 
individuals in the study with siblings who were also released from prison, but without psychiatric disorders. We tested 
whether any independent risk factors improved the prediction of mortality beyond age, sex, and criminal history.
Findings We identiﬁ ed 47 326 individuals who were imprisoned. During a median follow-up time of 5·1 years 
(IQR 2·6–7·5), we recorded 2874 (6%) deaths after release from prison. The overall all-cause mortality rate was 
1205 deaths per 100 000 person-years. Substance use disorders signiﬁ cantly increased the rate of all-cause mortality 
(alcohol use: adjusted HR 1·62, 95% CI 1·48–1·77; drug use: 1·67, 1·53–1·83), and the association was independent 
of sociodemographic, criminological, and familial factors. We identiﬁ ed no strong evidence that other psychiatric 
disorders increased mortality after we controlled for potential confounders. In people released from prison, 925 (34%) 
of all-cause deaths in men and 85 (50%) in women were potentially attributable to substance use disorders. Substance 
use disorders were also an independent determinant of external-cause mortality, with population attributable fraction 
estimates at 42% in men and 70% in women. Substance use disorders signiﬁ cantly improved the prediction of 
external-cause mortality, in addition to sociodemographic and criminological factors.
Interpretation Interventions to address substance use disorders could substantially decrease the burden of excess 
mortality in people released from prison, but might need to be provided beyond the immediate period after release.
Funding Wellcome Trust, Swedish Research Council, and the Swedish Research Council for Health, Working Life and 
Welfare.
Copyright © Chang et al. Open Access article distributed under the terms of CC BY.
Introduction
Every year more than 30 million people circulate through 
prisons,1 and most will eventually return to their 
communities. The period after release is associated with 
high risk for various health outcomes,2 and many studies 
have provided an epidemiological description of high 
mortality in people released from prison compared with 
the general population.3–10 In the USA, the ex-prisoner 
population was estimated as 5·4 million people,11 who 
account for about 12% of roughly 250 000 deaths from 
external causes every year.12 However, few studies have 
examined potential risk factors for these high mortality 
rates,13 and therefore, information for evidence-based 
prevention is scarce.14
Substance use disorders and psychiatric disorders are 
important potential risk factors that are highly prevalent 
in prisoners and potentially treatable.15,16 Although a few 
studies of post-release mortality have reported data for 
these disorders,3,17 none has fully examined the association 
between them and diﬀ erentiated the contribution of 
individual diagnoses. Mortality from drug overdose has 
been reported to be particularly high after release from 
prison.18 However, whether substance use disorders and 
other psychiatric disorders are causally associated with 
post-release mortality is uncertain, because prisoners are 
usually from deprived socioeconomic backgrounds,4 and 
both criminal behaviour and most psychiatric disorders 
tend to cluster in families. Whether substance use and 
other psychiatric disorders can be used to predict post-
release mortality is also unknown.
To inform preventive interventions for post-release 
mortality, additional research is needed to identify 
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potentially modiﬁ able risk factors. In this population-
based longitudinal study of people released from prison, 
we investigated the association between psychiatric 
disorders and post-release mortality. We aimed to address 
three main questions: ﬁ rst, whether substance use 
disorders and other psychiatric disorders are associated 
with mortality after prison release; second, what are the 
population eﬀ ects of identiﬁ ed risk factors on all-cause 
and external-cause mortality in people released from 
prison; and third, whether any of the identiﬁ ed risk 
factors can be used to predict external-cause mortality 
after release from prison.
Methods
Study population
We used data from several population-based registers 
in Sweden, which were linked with unique personal 
identiﬁ cation numbers.19 We selected a cohort of all 
people who have been imprisoned in Sweden since 
Jan 1, 2000, and released before Dec 31, 2009. We 
followed up the study individuals from the day of 
release until death, emigration from Sweden, or the 
end of the study (Dec 31, 2009). We obtained records of 
all criminal convictions since 1973 from the National 
Crime Register. From the National Patient Register, we 
obtained diagnoses for all inpatient psychiatric hospital 
admissions in Sweden since 1973, and outpatient care 
since 2001. We used the Cause of Death Register to 
obtain data for dates and causes of all deaths since 
1958. We collected data for yearly assessments of 
income, marital status, employ ment status, and 
education for all individuals aged 15 years or older 
using the Longitudinal Integration Database for Health 
Insurance and Labour Market Studies. We also 
identiﬁ ed the siblings of people in prison using the 
Multi-Generation Register. The study was approved by 
the Regional Ethics Committee at Karolinska Institutet, 
Stockholm, Sweden. All data were anonymised before 
they were analysed. 
Procedures
We deﬁ ned psychiatric disorders as any psychiatric 
diagnoses before release from prison, using data from the 
National Patient Register, which were based on ICD-8 
(1973–86, codes 290–315), ICD-9 (1987–96, codes 290–319), 
and ICD-10 (1997–2009, codes F00–F99). To investigate 
the diﬀ erences between individual psychiatric disorders, 
the following disorders were investigated: alcohol use 
disorder (ICD-8: 291, 303; ICD-9: 291, 303, 305A; ICD-10: 
F10); drug use disorder (ICD-8: 304; ICD-9: 292, 304, 305 
[except 305.A]; ICD-10: F11–F19); personality disorder 
(ICD-8: 301 [except 301.1]; ICD-9: 301 [except 301.B]; 
ICD-10: F60–61); attention deﬁ cit hyperactivity disorder 
(ADHD; ICD-8: not applicable; ICD-9: 314; ICD-10: F90); 
other developmental or childhood disorders (ICD-8: 308; 
ICD-9: 299A, 312, 313, 315; ICD-10: F80–F98 [except F90]). 
We assigned a hierarchical approach to diﬀ erentiate 
between schizophrenia-spectrum disorder, bipolar 
disorder, depression, and anxiety disorder, categorised as 
follows: schizophrenia-spectrum disorder (ICD-8: 295, 
297, 298.1–9, 299; ICD-9: 295, 297, 298 [except 298.A], 299; 
ICD-10: F20–F29), including schizoaﬀ ective disorders and 
Research in context
Evidence before this study
We searched PubMed from Jan 1, 2000, to Dec 31, 2014, for 
research about the association between psychiatric disorders 
and mortality in people released from prison. We used the 
following search terms: “psychiatric disorder*” or “mental 
disorder*” or “mental illness*” or “substance*”, and “death*” or 
“mortal*” or “suicid*” or “overdose*”, and “releas*”or “former*” 
or “ex”, and “prison*” or “incarce*” or “felon*” or “jail*” or 
“custod*” or “oﬀ end*”. We identiﬁ ed two systematic reviews of 
mortality in people released from prison, which identiﬁ ed 
18 studies and 25 studies, respectively, up to January, 2011. 
Since Jan 1, 2011, we identiﬁ ed a further six studies. Although 
the results of these studies have consistently shown that people 
released from prison are at increased risk for death following 
release, none of these has fully examined the association 
between psychiatric disorders and post-release mortality. In 
2012, Zlodre and Fazel called for further work to examine the 
contribution of mental illness on post-release mortality. 
Furthermore, we identiﬁ ed no studies that investigated the 
eﬀ ects of familial (genetic and environmental) factors on the 
potential link between psychiatric disorders and post-release 
mortality.
Implications of all the available evidence
Alcohol and drug use disorders, identiﬁ ed before prison release, 
were associated with substantially increased all-cause mortality 
and external-cause mortality. Additionally, little evidence 
suggested that other psychiatric disorders diagnosed before 
prison release increased all-cause or external-cause mortality 
rates. Substance use disorders signiﬁ cantly improved the 
prediction of external-cause mortality when added to a model 
with known sociodemographic and criminological factors.
Added value of this study
Our study is the ﬁ rst to investigate the eﬀ ect of substance use 
disorders and other psychiatric disorders on mortality after 
prison release, while taking into account both measured 
(sociodemographic and criminological) and unmeasured 
(familial) confounding factors. We also investigated individual 
causes of death, and noted that non-traﬃ  c accidents and suicide 
contributed to a large proportion of external-cause deaths. The 
use of a total population cohort of 47 326 individuals released 
from prison between 2000 and 2010 enabled us to provide 
precise eﬀ ect sizes, and to estimate the possible population 
eﬀ ect of substance use disorders on post-release mortality. 
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delusional disorders; bipolar disorder (ICD-8: 296.1, 296.3, 
296.8; 296A, 296C–296E, 296W; ICD-10: F30–31), but not 
schizophrenia-spectrum disorder; depression (ICD-8: 
296.2, 296.9, 298.0, 300.4; ICD-9: 296B, 296X, 298A, 300E, 
311; ICD-10: F32–39), but without schizophrenia-spectrum 
disorder or bipolar disorder; and anxiety disorder (ICD-8: 
300 [except 300.4], 305, 307; ICD-9: 300 [except 300.E], 306, 
308, 309; ICD-10: F40–48), but without schizophrenia-
spectrum disorder, bipolar disorder, or depression. The 
use of National Patient Register for psychiatric research is 
well established, and the National Patient Register data 
have good-to-excellent validity for a range of psychiatric 
disorders.20–23 We deﬁ ned substance use disorder as any 
diagnosis of alcohol or drug use disorders.
The main outcome was death after release from 
prison. The Cause of Death Register includes all people 
who, at the time of death, were registered as residents 
in Sweden, regardless of whether death occurred in 
Sweden or abroad, and it covers more than 99% of all 
deaths in Swedish residents.24 The underlying and 
contributing (secondary) causes of death are coded 
according to ICD-10,25 based on death certiﬁ cates issued 
by physicians or forensic doctors. We extracted both all-
cause mortality data and mortality data separated by 
ICD chapter in accordance with the underlying cause of 
death. Within external-cause mortality (ie, deaths 
caused by environmental events and circumstances, 
ICD-10 Chapter XX),25 we further examined deaths by 
traﬃ  c and non-traﬃ  c accidents, suicide, and homicide. 
In keeping with previous work, we included un-
determined deaths (ICD-10: Y10–Y34) as suicides.
We measured covariates, which were sex, age, 
immigration status (deﬁ ned as being born outside of 
Sweden), criminological factors (length of incarceration 
[categorised into four levels], violent index oﬀ ence, any 
previous violent crime), and sociodemographic factors 
(civil status [categorised into four levels], employment, 
and highest level of completed education [categorised 
into three levels], disposable income, and neighbourhood 
deprivation) at the year of release. We did not replace 
missing data by imputation or other methods in the 
principal analyses, but did so in a sensitivity analysis.
Statistical analysis
We calculated mortality (the number of deaths divided by 
person-years at risk) and 95% CIs for all-cause death, 
11 causes of death by ICD chapter, and subcauses of 
external causes. We used SAS 9.4 software for all 
statistical analysis.
We used Kaplan-Meier survival curves to show the 
timing of post-release mortality for prisoners with and 
without substance use disorders, and prisoners with and 
without any other psychiatric disorders. To explore the 
association between individual disorders and post-release 
mortality, we constructed Cox proportional hazard 
models for each diagnosis investigated. We calculated 
hazard ratios (HRs) with progressive adjustment for age 
and immigration status, criminological, and socio-
demographic factors, sex, and alcohol and drug use 
disorders. We veriﬁ ed the proportional hazards 
assumption by visually inspecting the Kaplan-Meier 
Curves and testing with Schoenfeld residuals. To 
examine whether the association between psychiatric 
disorders and death was explained by familial factors, we 
used a sibling-comparison approach, which we did by 
ﬁ tting a ﬁ xed-eﬀ ect model26 (stratiﬁ ed Cox regression) to 
the subsample of full-siblings who were imprisoned, to 
adjust for all unmeasured genetic and environmental 
factors that were shared by siblings.
In addition to being signiﬁ cantly associated with the 
outcome, a clinically important risk factor should also 
have substantial population eﬀ ect or predictive validity to 
identify high-risk individuals. To assess the eﬀ ect of 
psychiatric disorders on post-release mortality, we used 
the population attributable fraction (PAF). The PAF 
measures the proportion of deaths that can be attributed 
to a risk factor, with the assumption that a causal 
association exists. In the presence of confounding, PAF 
can be calculated as,27 
where Pr (X = 1 | Y = 1) is the probability of exposure given 
outcome and HRa is the adjusted HR. We calculated the 
CIs of PAF using the Bonferroni inequality method.28
To assess the incremental predictive validity of 
psychiatric disorders for post-release mortality, we 
examined whether substance use disorder or any other 
psychiatric disorder could improve the prediction of 
external-cause mortality in released prisoners. We 
focused on external-cause mortality because these deaths 
are potentially preventable, whereas other causes of 
death might be mainly caused by age. A good predictor 
should improve discrimination, calibration, and re-
classiﬁ cation. We assessed discrimination—the ability of 
a model to distinguish between those who will and will 
not have the outcome—using Harrell’s c-index, which 
varies from 0·5 to 1·0.29 The c-index has a similar 
interpretation to the area under the receiver operating 
curve, but is more appropriate for survival data 
characterised by censored observations. We statistically 
assessed calibration, which examines goodness of ﬁ t, 
using the likelihood ratio test. The likelihood ratio test 
suggests whether the addition of a new variable 
signiﬁ cantly improves the ﬁ t of a model. We assessed 
reclassiﬁ cation using change in Royston’s R², which 
shows whether the addition of a new variable improves 
the percentage of variance explained by the model.30 For 
incremental predictive validity analysis, we included, 
age, sex, immigration status, criminological factors, 
sociodemographic factors, and previous self-harm in the 
baseline model as a-priori factors.17 We followed STROBE 
guidelines (appendix).
Pr (X = 1 | Y = 1) (1 – HRa
–1)
See Online for appendix
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. ZC had full access to all the data in the study 
and ZC and SF had ﬁ nal responsibility for the decision to 
submit for publication.
Results
We identiﬁ ed 47 326 people in prison during the 
study period, and followed them up for a total of 
238 457 person-years after release. Table 1 shows baseline 
socio demographic and criminological information and 
psychiatric diagnoses in men and women who were 
imprisoned. 18 563 (42%) of 43 840 men and 2233 (64%) 
of 3486 women had any psychiatric disorder, and preva-
lence of alcohol and drug use was high. We identiﬁ ed 
1458 pairs of siblings who were both imprisoned.
During a median follow-up time of 5·1 years 
(IQR 2·6–7·5), 2874 (6%) of study individuals died after 
release from prison (table 2). Median age at death was 
49·1 years (IQR 38·4–58·0). The median time from 
release to death was 3·5 years (1·7–5·4). 417 people (15% 
of deaths) died in the ﬁ rst year and 856 (30%) died within 
2 years. The overall all-cause mortality rate was 
1205 deaths per 100 000 person-years (table 2), and the 
rate was slightly higher in men than in women. 
1276 deaths (44% of deaths) were attributed to external 
causes, which were mainly non-traﬃ  c accidents and 
suicides (table 2). Cardiovascular causes and cancer were 
other major causes of deaths.
The appendix shows the overall Kaplan-Meier curve 
for all-cause mortality in people released from prison. 
Individuals with previous diagnoses of substance use 
disorders were more likely to die than were individuals 
without substance use disorders (ﬁ gure 1). In men, the 
estimated probability of death within 5 years after 
release was 10·2% (95% CI 9·6–10·7) for those with 
substance use disorders and 3·2% (3·0–3·4%) for those 
without. In women, the probability of death within 
5 years after release was 6·5% (5·2–7·8) for those with 
substance use disorders and 2·6% (1·8–3·5) for those 
without. We identiﬁ ed similar diﬀ erences in mortality 
rates in people with and without any other psychiatric 
disorder (ﬁ gure 1).
Overall, the strongest associations were for alcohol and 
drug use disorders, and the associations remained after 
we adjusted for possible confounders (table 3). The 
associations between other psychiatric disorders and all-
cause mortality were signiﬁ cant in model 1, which we 
adjusted for age, sex, and immigration status, but mostly 
disappeared after adjustment for possible confounders 
and alcohol and drug use disorders (models 2 and 3). We 
identiﬁ ed a similar pattern of results for the associations 
between individual psychiatric disorders and external-
cause mortality (table 3). Sensitivity analysis for all-cause 
and external-cause mortality, stratiﬁ ed by sex, also showed 
a similar pattern of results (appendix). We identiﬁ ed 
similar results in analysis with multiple imputations for 
missing values.
Because of the association between substance use 
disorders and post-release mortality, we further examined 
whether this association could be explained by familial 
factors by using siblings who were also imprisoned for 
comparison. A small proportion (20%) of siblings had 
overlapping sentences. The association between substance 
use disorders and all-cause mortality did not change 
substantially after adjustment for sociodemographic and 
criminological factors (adjusted model) and familial 
Men (n=43 840) Women (n=3486)
Person-years at risk 221 522 16 935
Deaths during follow-up 2703 (6%) 171 (5%)
Age group (years)
16–24 8466 (19%) 361 (10%)
25–39 17 291 (39%) 1409 (40%)
≥40 18 083 (41%) 1716 (49%)
Civil status*
Unmarried 26 910 (65%) 1614 (49%)
Married 5066 (12%) 537 (16%)
Divorced 9105 (22%) 1094 (33%)
Widowed 222 (<1%) 67 (2%)
Highest education (years)*
<9 19 546 (47%) 1765 (53%)
9–11 19 174 (46%) 1322 (40%)
≥12 2583 (6%) 225 (7%)
Employed* 8045 (20%) 355 (11%)
Immigrant 13 710 (31%) 806 (23%)
Disposable income*† 775 (473 to 1100) 749 (444 to 1082)
Neighbourhood deprivation*‡ 0·38 (–0·17 to 1·48) 0·35 (–0·15 to 1·46)
Length of incarceration (months)
<6 30 155 (69%) 2608 (75%)
6–11 7270 (16%) 506 (14%)
12–23 4408 (10%) 283 (8%)
≥24 2007 (5%) 89 (3%)
Violent index oﬀ ence 17 294 (39%) 643 (18%)
Previous violent crime 23 960 (55%) 1112 (32%)
Previous psychiatric disorder
Any psychiatric disorder 18 563 (42%) 2233 (64%)
Alcohol use disorder 9276 (21%) 968 (28%)
Drug use disorder 9597 (22%) 1438 (41%)
Personality disorder 2320 (5%) 353 (10%)
Attention deﬁ cit hyperactivity disorder 546 (1%) 51 (1%)
Other developmental or childhood disorder 979 (2%) 139 (4%)
Schizophrenia-spectrum disorder 1237 (3%) 130 (4%)
Bipolar disorder 216 (<1%) 35 (1%)
Depression 2553 (6%) 418 (12%)
Anxiety disorder 3247 (7%) 534 (15%)
Data are number (%) or median (IQR). *2573 men and 174 women had missing values for civil status, highest 
education, employment, disposable income, and neighbourhood deprivation. †100 Swedish Krona. ‡Standardised 
score of the overall degree of socioeconomic deprivation in an individual’s residential area.
Table 1: Baseline sociodemographic characteristics and follow-up data 
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factors (sibling model; ﬁ gure 2). The pattern of results was 
the same for external-cause mortality (ﬁ gure 2).
Assuming causality, 2703 men died after release from 
prison and 925 of these deaths were potentially attributable 
to substance use disorders, corresponding to a PAF of 34% 
for all-cause mortality (appendix). In women, 85 of 171 
deaths were potentially attributable to substance use (PAF 
50%). For external-cause mortality, 503 of the 1202 deaths in 
men were potentially attributable to substance use (PAF 
42%). In women, 52 of 74 external-cause deaths were 
potentially attributable to substance use (PAF 70%).
We examined the predictive value of substance use 
disorders and any other psychiatric disorders (appendix). 
The addition of substance use disorders to a baseline 
model, which included sociodemographic factors, 
criminological factors, and self-harm, best predicted 
external-cause death because it was associated with the 
largest increase in Harrell’s c-index (5·0%; appendix). 
The addition of substance use disorders also signiﬁ cantly 
improved calibration and reclassiﬁ cation, as suggested 
by the likelihood ratio test (Δχ² 224·4, p<0·0001) and 
Royston’s R²(Δ% 8·1, 95% CI 2·2–13·9). Addition of any 
other psychiatric disorders did not further improve 
predictive accuracy (see appendix for HRs for all risk 
factors in this model). We identiﬁ ed the same pattern of 
results in relation to predictive models for all-cause 
mortality (data not shown).
Discussion
In this longitudinal cohort study, substance use disorders 
were associated with a substantially increased rate of 
mortality in people released from prison, and the 
association remained even when we compared siblings 
without substance use disorders who were also in prison, 
which adjusts for unmeasured genetic and environmental 
factors. A large proportion of deaths among released 
prisoners could be attributed to substance use. 
Additionally, we identiﬁ ed little evidence that other 
psychiatric disorders increased the all-cause or 
external-cause mortality rate. To our knowledge, this is 
the ﬁ rst time the association between psychiatric 
disorders and post-release mortality has been examined 
with adjustment for sociodemographic, criminological, 
and familial factors. Our estimates of the population 
eﬀ ect of substance use disorders on post-release mortality 
are also novel.
Substance use disorders were associated with a 
substantially increased rate of post-release mortality. 
More importantly, our results suggested that the 
association was independent from the contribution of 
sociodemographic, criminological, and familial factors, 
supporting a causal eﬀ ect of substance use disorders. For 
individuals with substance use disorders in other 
settings, transitions, such as hospital discharge and 
discontinuation of treatment, have been associated with 
increased mortality.31,32 Possible explanations include 
diminished physiological tolerance to substances after 
release33 and increased risk of fatal overdose after 
release.3,34 Additionally, the physiological age of people in 
prison has been estimated to be roughly 10–15 years 
older than their chronological ages,35 and cellular and 
brain imaging studies have provided evidence that 
substance use is associated with accelerated biological 
ageing.36
Overall Men Women
Deaths Mortality Deaths Mortality Deaths Mortality
All causes 2874 (100%) 1205 (1161–1249) 2703 (100%) 1220 (1174–1266) 171 (100%) 1010 (858–1161)
Certain infectious and parasitic diseases (chapter I) 92 (3%) 39 (31–46) 82 (3%) 37 (29–45) 10 (6%) 59 (22–96)
Neoplasms (chapter II) 305 (11%) 128 (114–142) 282 (10%) 127 (112–142) 23 (13%) 136 (80–191)
Endocrine, nutritional and metabolic diseases (chapter IV) 39 (1%) 16 (11–21) 37 (1%) 17 (11–22) 2 (1%) 12 (0–28)
Mental and behavioural disorders (chapter V) 195 (7%) 82 (70–93) 185 (7%) 84 (71–96) 10 (6%) 59 (22–96)
Diseases of the nervous system (chapter VI) 27 (1%) 11 (7–16) 25 (1%) 11 (7–16) 2 (1·2%) 12 (0–28)
Diseases of the circulatory system (chapter IX) 507 (18%) 213 (194–231) 486 (18%) 219 (200–239) 21 (12·3%) 124 (71–177)
Diseases of the respiratory system (chapter X) 83 (3%) 35 (27–42) 81 (3%) 37 (29–45) 2 (1%) 12 (0–28)
Diseases of the digestive system (chapter XI) 222 (8%) 93 (81–105) 203 (8%) 92 (79–104) 19 (11%) 112 (62–163)
Symptoms, signs and abnormal clinical and laboratory 
ﬁ ndings, not elsewhere classiﬁ ed (chapter XVIII)
110 (4%) 46 (38–55) 106 (4%) 48 (39–57) 4 (2%) 24 (0–47)
Other non-external causes* 18 (1%) 8 (4–11) 14 (1%) 6 (3–10) 4 (2%) 24 (0–47)
External causes of morbidity and mortality (chapter XX) 1276 (44%)† 535 (506–564) 1202 (44%)† 543 (512–573) 74 (43%) 437 (337–537)
Traﬃ  c accidents 158 (6%) 66 (56–77) 152 (6%) 69 (58–80) 6 (4%) 35 (7–64)
Non-traﬃ  c accidents 557 (19%) 234 (214–253) 528 (20%) 238 (218–259) 29 (17%) 171 (109–234)
Suicide 471 (16%) 198 (180–215) 435 (16%) 196 (178–215) 36 (21%) 213 (143–282)
Homicide 83 (3%) 35 (27–42) 80 (3%) 36 (28–44) 3 (2%) 18 (0–38)
Data are n (%) or mortality per 100 000 person-years (95% CI). Causes are classiﬁ ed by ICD-10 chapters. *ICD-10 chapters III, VII, VIII, XII, XIII, XIV, XV, XVI, and XVII. †Seven deaths were categorised as ICD-10 Y35–Y98.
Table 2: Mortality rates 
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Our study, with long follow-up, has several implications. 
First, our results show that substance use disorders had a 
persistent eﬀ ect on risk of mortality after release, beyond 
the ﬁ rst few weeks or months. With the current focus on 
transitions in many clinical guidelines,37,38 our ﬁ ndings 
suggest that this alone might not lead to large reductions 
in mortality of people released from prisons, and 
guidelines for the clinical care of these individuals need 
to be reviewed. Research has suggested the need to shift 
treatment for substance use disorder from an acute-care 
model to a chronic disease-management model.39 Future 
research is needed about how treatment in prison can be 
linked with community services and primary care to 
achieve a cost-eﬀ ective service model with limited health-
care resources. Second, although alcohol use disorder is 
as prevalent as drug use disorder and the increased 
mortality risks are similar, some countries do not give it 
the same level of funding or service provision.40 For 
example, in 2010–11 in England and Wales, nearly half of 
prisons had no alcohol-related services or programmes 
available.41,42 Furthermore, in some countries, much of 
current provision only targets alcohol use disorder if it 
co-occurs with drug problems. Third, our results 
underscore the potential health beneﬁ ts of alternatives to 
imprisonment, such as regular drug monitoring in the 
community, or diversion to treatment.43 Fourth, linkage 
to community services and adherence to treatment is 
likely to be important for people released from prison 
who have substance use disorders.43 Trial evidence has 
shown that targeted interventions, such as maintenance 
of opioid substitution treatment and participation in peer 
self-help organisations (eg, Alcoholics Anonymous), 
promote abstinence and produce beneﬁ ts for individual 
health and the public good.43 Contingency management 
improves treatment adherence.44 Finally, appropriate and 
sustainable epidemiological systems will be needed to 
survey alcohol and drug use, overall and cause-speciﬁ c 
mortality, and eﬀ ectiveness of health-care services for 
populations of former prisoners.45,46
In our study, excess mortality associated with sub-
stance use in prisoners was less than that reported for 
such disorders in the general population.47 The eﬀ ect of 
substance use disorders on mortality in people released 
from prison might be less than that in the general 
population because prisoners have cumulative risk 
factors and a high baseline mortality. Another possible 
explanation for this diﬀ erence is that we have more 
comprehensively adjusted for sociodemographic co-
variates than have similar studies in the general 
population.
We identiﬁ ed little evidence that other psychiatric 
disorders, including schizophrenia, bipolar disorder, and 
depression, independently increased post-release 
mortality. Although these disorders were linked with 
increased mortality in the initial analysis, the associations 
were not signiﬁ cant after we adjusted for socio-
demographic and criminological factors and comorbid 
substance use disorders, suggesting that the excess 
mortality rate for the disorders was mainly explained by 
these factors. This ﬁ nding was unexpected, and contrasts 
Figure 1: Kaplan-Meier Curves for all-cause mortality
Individuals released from prison with and without (A) substance use disorders or (B) other psychiatric disorders.
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with previous research that has shown psychiatric 
disorders to increase mortality risk during incarceration.48 
Possible explanations are that previous research did not 
adequately assess potential confounders, such as 
comorbid substance use disorders, or that the psychiatric 
determinants for death after release are diﬀ erent from 
those during incarceration. Alternatively, for some 
individuals, drug and alcohol use disorders could mask 
an underlying mental illness. In particular, comorbid 
diagnoses might be under-reported in individuals with 
alcohol dependency. Although we had a relatively large 
sample, we cannot rule out the possibility of small eﬀ ects 
of other psychiatric disorders on post-release mortality.
PAFs assume a causal relation between substance use 
disorders and post-release mortality. In this study, we have 
not only adjusted for sociodemographic and crimino logical 
factors, but also accounted for unmeasured familial 
confounding by using comparisons with siblings who were 
released from prison. Although the results are consistent 
with a causal hypothesis, they remain based on 
observational data and need to be replicated with other 
study designs. Nevertheless, our results underscore the 
substantial contribution of substance use disorders to the 
increased mortality after prison release, and the PAF was 
increased further for external-cause mortality. In our 
sample, the 1276 external-cause deaths accounted for 2·7% 
of all external-cause mortality (47 179 deaths) in Sweden 
during the study period (2000–09),24 and substance use 
disorders in released prisoners contributed to 555 deaths 
(1·1% of all external-cause deaths). This contribution to 
external-cause mortality could be substantially increased in 
counties with higher incarceration rates than that of 
Sweden. For example, if our ﬁ ndings were replicated in the 
USA, about 9% of external-cause mortality in the US adult 
general population would potentially be preventable if 
substance use disorders were fully treated in all people 
released from jail and prison and assuming causality 
between substance use disorders and mortality (see 
appendix for calculation).
Risk assessment instruments are widely used by 
criminal justice systems to identify high-risk prisoners 
and estimate their risk of reoﬀ ending.49 However, little 
information exists on what predicts mortality after 
release from prison.13 Using the current sample, we 
report that substance use disorders signiﬁ cantly 
improved prediction of external-cause mortality in 
addition to the information available from routinely 
collected factors, including sociodemographic and 
criminological factors. Moreover, the predictive value of 
substance use disorders was stronger than that of other 
psychiatric disorders. Our ﬁ ndings suggest that substance 
use disorders, together with key sociodemographic and 
criminological factors, pro duced moderate levels of 
predictive accuracy and might help to identify high-risk 
groups for targeted intervention (eg, re-induction onto 
opioid substitution treatment).50 Further studies are 
needed to examine the validity of our ﬁ nding in 
independent samples.
Therapies for substance use disorders, including 
pharmacological treatment, have been shown to be 
eﬀ ective in reduction of drug misuse and related 
problems.51 However, evidence that any particular 
treatment can reduce mortality is not yet conclusive,52 
which might be partly because mortality remains a rare 
outcome, even in high-risk groups, especially if follow-up 
is not suﬃ  ciently long. Further studies with extended 
follow-up are needed to investigate the ability of treatment 
for substance use disorders to reduce mortality. As the 
Figure 2: Association between substance use disorder and mortality after 
prison release
Baseline model adjusted for age, sex, and immigration status. Adjusted model 
adjusted for age, sex, immigration status, and sociodemographic and 
criminological covariates. Sibling model adjusted for all factors shared by siblings 
and measured covariates, based on 1458 pairs of prisoners who were full siblings. 
All-cause mortality
Baseline model
Adjusted model
Sibling model
External-cause mortality
Baseline model
Adjusted model
Sibling model
2·62 (2·43–2·83)
2·25 (2·07–2·46)
2·34 (1·85–2·98)
3·39 (3·01–3·82)
2·93 (2·57–3·34)
3·54 (2·29–5·47)
Hazard ratio (95% CI)
0·5 1 2 3 4 5
Model 1* Model 2† Model 3‡
All-cause mortality
Alcohol use disorder 2·11 (1·95–2·29) 1·85 (1·69–2·02) 1·62 (1·48–1·77)
Drug use disorder 2·25 (2·08–2·43) 1·90 (1·74–2·08) 1·67 (1·53–1·83)
Personality disorder 1·41 (1·24–1·61) 1·16 (1·00–1·34) 0·84 (0·72–0·98)
Attention deﬁ cit hyperactivity disorder 1·81 (1·18–2·79) 1·37 (0·83–2·24) 1·12 (0·68–1·84)
Other developmental or childhood 
disorder
1·41 (1·08–1·85) 1·30 (0·98–1·73) 1·17 (0·88–1·56)
Schizophrenia-spectrum disorder 1·36 (1·12–1·64) 1·13 (0·92–1·40) 0·84 (0·68–1·04)
Bipolar disorder 1·41 (0·87–2·27) 1·18 (0·68–2·04) 0·94 (0·54–1·62)
Depression 1·31 (1·14–1·51) 1·20 (1·03–1·40) 0·99 (0·85–1·16)
Anxiety disorder 1·16 (1·01–1·33) 1·12 (0·97–1·30) 0·95 (0·82–1·10)
External-cause mortality
Alcohol use disorder 2·23 (1·97–2·53) 1·99 (1·73–2·28) 1·54 (1·34–1·78)
Drug use disorder 3·20 (2·85–3·59) 2·70 (2·37–3·07) 2·43 (2·13–2·78)
Personality disorder 1·92 (1·60–2·31) 1·53 (1·24–1·87) 1·01 (0·82–1·25)
Attention deﬁ cit hyperactivity disorder 1·74 (1·04–2·91) 1·53 (0·88–2·65) 1·17 (0·67–2·03)
Other developmental or childhood 
disorder
1·38 (1·00–1·91) 1·23 (0·87–1·74) 1·08 (0·76–1·52)
Schizophrenia-spectrum disorder 1·77 (1·36–2·32) 1·43 (1·06–1·92) 0·93 (0·69–1·26)
Bipolar disorder 1·44 (0·65–3·22) 1·09 (0·41–2·92) 0·84 (0·31–2·24)
Depression 1·74 (1·41–2·14) 1·60 (1·27–2·01) 1·24 (0·99–1·57)
Anxiety disorder 1·19 (0·97–1·46) 1·11 (0·89–1·39) 0·89 (0·71–1·11)
Data are hazard ratios (95% CI). *Adjusted for age, sex, and immigration status. †In addition to covariates in model 1, 
adjusted for sociodemographic and criminological covariates. ‡In addition to covariates in model 2, adjusted for 
alcohol and drug use disorder.
Table 3: Association between individual psychiatric disorders and mortality after prison release
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absolute numbers of people in prison with substance use 
disorders are large worldwide, improvements to their 
treatment might have a substantial eﬀ ect.
Our study has three main limitations. First, the 
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reduced risk of adverse outcomes such as death. 
Consequently, our ﬁ ndings might be conservative 
estimates of the actual eﬀ ect of substance use disorders 
on post-release mortality. Third, the ﬁ ndings were based 
on Swedish population data, and generalisation to other 
countries with diﬀ erent criminal justice systems need 
clariﬁ cation. Although Sweden has a low incarceration 
rate compared with other countries,53 the prevalence of 
substance use disorders and severe psychiatric disorders 
reported in this study was largely similar to those in the 
USA and other high-income countries. For example, 
prevalence is estimated to be 26% for alcohol use disorder 
and 25% for drug use disorder in men in prison in the 
USA,15 compared with 21% for alcohol use disorder and 
22% for drug use disorder in the current sample. For US 
female prisoners, prevalence is estimated to be 20% for 
alcohol use disorder and 45% for drug use disorder,15 
compared with 28% for alcohol use disorder and 41% for 
drug use disorder in our sample. Furthermore, in a recent 
systematic review,16 the pooled prevalence of psychotic 
disorders was 3·6% in men and 3·9% in women 
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Our results show high mortality in people released 
from prison, and the substantial contribution of substance 
use disorders to this mortality. We provide evidence that 
supports a causal role for substance use disorders in post-
release mortality, and that these disorders might be useful 
to identify high-risk groups. Future research is needed to 
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many countries, jails and prisons are an important 
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who are out of the reach of conventional health-care 
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people released from custody, but also improve both 
public health and safety.54,55
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